In its first full year on the market, West Conshohocken-based Madrigal Pharmaceuticals’ flagship drug Rezdiffra nearly got to blockbuster status, bringing in $958.4 million in 2025, writes John George for the Philadelphia Business Journal.
The treatment for MASH, a progressive liver disease metabolic dysfunction-associated steatohepatitis, marked the company’s largest advancement since being founded in 2011. The success comes even as competitors for the drug enter the market.
“We didn’t just launch a product,” said Madrigal CEO Bill Sibold, “we built a market from scratch. … Remember, MASH was long viewed as the graveyard of drug development – no treatments, no market, and skepticism that one would ever exist.”
Madrigal steadily expanded its product-commercialization team as the drug continued to perform successfully in late-stage clinical testing. It employed nearly 900 people. Its long-term strategy focused on educating prescribers, primarily hepatologists and gastroenterologists, one practice at a time.
The company identified roughly 14,000 specialists as potential high-volume MASH prescribers. It is also working with health insurers to ensure patients can access the treatment without facing unnecessary barriers.
This approach drove a 438 percent sales increase in 2025. It rose from $180 million the previous year to $958.4 million.
Read more about Conshohocken’s Madrigal Pharmaceuticals in the Philadelphia Business Journal.
